This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through ...
Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback